Post by Halozyme, Inc.

Looking ahead to the Controlled Release Society (CRS) 2026 Annual Meeting, where Halozyme’s David Kang, Director, Drug Delivery, and Chris Wahl, Chief Scientific Officer, will participate in multiple sessions, including: Workshop: Advancing Technologies and Strategies for Subcutaneous Drug Development and Delivery, hosted by the Subcutaneous Drug Development & Delivery Consortium on July 6 from 12:30 – 4:30 PM, featuring presentations on: Rethinking SC Administration for ADCs and LNPs 1:25 – 1:30 PM Presented by Chris Wahl Value, Access, and the Health Economics of SC Administration 3:35 – 3:50 PM Presented by David Kang These sessions will explore evolving scientific, clinical, and economic considerations shaping the development and adoption of SC therapeutics. We will also participate in Technical Session VII on Nanomedicine and Nanoscale Delivery XI July 9 | 2:30 – 4:30 PM Presented by Chris Wahl If you’re attending CRS, we hope you’ll join these discussions. #CRS2026